Voclosporin

CHEMBL5314379 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1214.6 g/mol

LogP

7.9

Phase

4

Voclosporin is a novel calcineurin inhibitor structurally related to cyclosporine that suppresses T-cell activation by blocking calcineurin-mediated dephosphorylation of NFAT transcription factors, thereby reducing IL-2 production and T-cell proliferation in immune-mediated diseases. It is approved for the treatment of adult patients with active lupus nephritis in combination with immunosuppressive background therapy. Compared to cyclosporine, voclosporin has a more predictable pharmacokinetic profile and additional podocyte-stabilizing effects.

Masse moléculaire

1214,6000 g/mol

LogP

7,90

TPSA

279,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Psoriasis Systemic Lupus Erythematosus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C

InChI

InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1

Molecular Formula

C63H111N11O12

HBD / HBA

5 / 12

Liaisons Rotatives

16

Atomes Lourds

86

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Voclosporin is a novel calcineurin inhibitor structurally related to cyclosporine that suppresses T-cell activation by blocking calcineurin-mediated dephosphorylation of NFAT transcription factors, thereby reducing IL-2 production and T-cell proliferation in immune-mediated diseases. It is approved for the treatment of adult patients with active lupus nephritis in combination with immunosuppressive background therapy. Compared to cyclosporine, voclosporin has a more predictable pharmacokinetic profile and additional podocyte-stabilizing effects.

Yes, Voclosporin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314379. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918486. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Voclosporin sur PillFYI

Structure

Données Clés

Formule: C63H111N11O12
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.